NAT10

Across TCGA pan-cancer cohorts, NAT10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAT10 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NAT10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAT10 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where NAT10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.574	0.906	<.001	121	view →
PDAC	OS	Quartile	II,III,IV	0.269	0.597	.004	22	view →
LUAD	DFS	Median	II,III,IV	0.971	0.735	.001	20	view →
LSCC	DFS	Tertile	II,III,IV	0.853	0.505	.015	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAT10–CCRCC (DFS)

Open the CCRCC breakdown →